About this document
177Lu-DOTATATE for Neuroendocrine Tumors by msghurab is a document available to read on EtoBox.
The document discusses the implementation of 177Lu-DOTATATE for treating somatostatin receptor-positive neuroendocrine tumors (NETs), highlighting its FDA approval and significant impact on patient management. It reviews patient selection criteria, administration methods, safety considerations, and reimbursement guidelines, emphasizing the importance of multidisciplinary teams in evaluating treatment options. The paper aims to provide practical clinical insights for healthcare professionals involved in the
- Author
- msghurab
- Language
- EN